Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized trial of anti-GD2 immunotherapy regimens in high-risk neuroblastoma
2013-004481-34Phase 2Terminated
- Sponsor
- University of Cologne
- Start
- Aug 2014
- Modality
- Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dinutuximab, aldesleukin and sargramostim in neuroblastoma (3 arms), sponsored by University of Cologne. Primary endpoints: Safety and Tolerability. Started Aug 2014; status: terminated.
02
Drugs
dinutuximabaldesleukinsargramostim
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on 2013-004481-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004481-34.